Login to Your Account

Cardiome, Astellas' I.V. Heart Drug Kynapid Marching Forth

By Randall Osborne

Monday, December 17, 2007
Last week's FDA panel nod for Cardiome Pharma Corp.'s intravenous atrial fibrillation/flutter drug vernakalant - lately branded Kynapid - came with the expected provisos, and put the company in strong position as the race to market continues for I.V. and oral versions of AF drugs. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription